柳藥集團(603368.SH):2023年淨利潤同比增長20.7%
格隆匯3月19日丨柳藥集團(603368.SH)公佈2023年度業績快報,報吿期內,公司實現營業總收入2,081,190.29萬元,同比增長9.23%;實現歸屬於上市公司股東的淨利潤84,676.39萬元,同比增長20.70%。
在醫藥批發板塊,公司強化供應商合作,搶抓優質新品,積極拓展藥械耗材SPD項目,推動集採集配模式落地,穩步提升批發市場規模尤其器械耗材市場份額。在醫藥零售板塊,公司持續拓展零售門店佈局,優化品種結構,發展處方外延、慢病管理、DTP等專業創新業務,推動零售業務提質增利。在醫藥工業板塊,公司穩步提升工業產能規模、不斷豐富品種,整合商業渠道資源,加快自產品種覆蓋廣西市場的同時持續拓展區外市場,工業板塊營收和淨利繼續保持較快增長,對公司的利潤貢獻持續擴大,成為公司新的利潤增長點。公司中藥配方顆粒項目已完成450多個品種備案工作,客户開發持續加快,成為新的業務增量,為未來實現業績放量奠定基礎。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.